Loading
Cardiovascular Disease and Adiposity / Liver Disease Diagnosis and Treatment · Journal article
International Journal of Innovative Technologies in Social Science · September 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review of MASLD (formerly NAFLD) that synthesizes current understanding of disease pathogenesis, diagnostic approaches, and therapeutic options including lifestyle modification and emerging pharmacotherapy and precision medicine strategies. It does not present new clinical evidence but rather integrates existing knowledge to guide contemporary clinical practice and identify future research directions.
Journal article. Patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
MASLD is linked to global epidemics of obesity, type 2 diabetes, and metabolic syndrome Pathogenesis involves insulin resistance, oxidative stress, gut dysbiosis, and genetic variants (PNPLA3 and TM6SF2) Diagnostic methods range from liver biopsy to elastography, MRI-PDFF, and non-invasive biomarkers
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize the evolving nomenclature and multifactorial nature of MASLD, use contemporary diagnostic approaches beyond biopsy, and consider both lifestyle and pharmacological interventions. The emphasis on precision medicine suggests future clinical decisions may be informed by genetic profiling and AI-driven risk stratification.
A narrative review synthesizing disease nomenclature, pathophysiology, diagnostics, and therapeutic approaches including emerging precision medicine concepts, without reporting original clinical trial data or systematic evidence synthesis.
Clinicians should recognize the evolving nomenclature and multifactorial nature of MASLD, use contemporary diagnostic approaches beyond biopsy, and consider both lifestyle and pharmacological interventions. The emphasis on precision medicine suggests future clinical decisions may be informed by genetic profiling and AI-driven risk stratification.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Non-Alcoholic Fatty Liver Disease (NAFLD), recently reclassified as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), represents one of the most significant challenges in modern hepatology and metabolic medicine (Rinella et al., 2023). This paper examines the evolution of the disease's nomenclature and pathophysiological concepts, emphasizing its direct link to the global epidemic of obesity, type 2 diabetes, and metabolic syndrome (Younossi et al., 2016). The review details the multifactorial pathogenesis of the disease, addressing the roles of insulin resistance, oxidative stress, gut dysbiosis, and genetic predispositions (including variants in the PNPLA3 and TM6SF2 genes) (Eslam et al., 2022; Kozlitina et al., 2014). It provides a comprehensive overview of contemporary diagnostic methods, ranging from the traditional "gold standard" of liver biopsy to advanced imaging techniques such as elastography and MRI-PDFF, alongside non-invasive biomarkers (EASL, 2021; Vilar-Gomez et al., 2024). Furthermore, the paper compares the significance of lifestyle modifications with the rapidly evolving landscape of pharmacotherapy, including GLP-1 receptor agonists (Newsome et al., 2021). A primary focus is placed on the potential of precision medicine; the integration of genetic profiling, artificial intelligence, and machine learning offers new avenues for risk stratification and the personalization of therapy (Plompen et al., 2023). The paper concludes by addressing diagnostic limitations and identifying future research priorities aimed at optimizing patient care for MASLD in the era of personalized medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.